<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811356</url>
  </required_header>
  <id_info>
    <org_study_id>111319</org_study_id>
    <nct_id>NCT00811356</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria</brief_title>
  <official_title>A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the study drug (antimalarial medication) is safe&#xD;
      when given to healthy subjects as a single dose or as repeated doses, to understand the&#xD;
      effect of food on single doses of study drug and to determine if the study drug has an effect&#xD;
      on other approved medications such as rosiglitazone and rosuvastatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malaria is a type of parasitic infection, common in tropical and subtropical regions of the&#xD;
      world, including parts of the Americas, Asia, and Africa. In recent years there has been a&#xD;
      rapid spread of drug resistant malaria which makes it necessary to develop new antimalarial&#xD;
      treatments. In animal studies, GSK932121 is shown to be able to kill the malaria parasite and&#xD;
      is fully active against drug resistant malaria parasites. It is hoped that information&#xD;
      collected on this study will lead to an improved treatment for malaria.&#xD;
&#xD;
      This is a first time in human fusion study which has 3 parts:&#xD;
&#xD;
      Part A - single dose escalation/ food effect: a study where the study drug is given once&#xD;
      only- first at the lowest dose of in a group of participants and the dose increased only if&#xD;
      the previous dose is found to be safe. It also looks at the effect of food on the study drug&#xD;
      in the body Part B - repeat dose escalation: a study where the study drug will be given daily&#xD;
      for up to 7 days - first at a lower dose in a group of participants and the dose increased&#xD;
      for the next group only if the previous dose is found to be safe and Part B - drug-drug&#xD;
      interaction: a study where the study drug will be given daily for up to 7 days at a dose&#xD;
      determined to be safe in previous groups of participants and looking at the effect of the&#xD;
      study drug on other specific approved medications (such as rosiglitazone--a diabetic&#xD;
      medication and rosuvastatin--a cholesterol lowering medication) in the body.&#xD;
&#xD;
      Safety will be assessed by measurement of vital signs, cardiac monitoring, spirometry,&#xD;
      collection of adverse event assessments, renal biomarkers and laboratory safety tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    safety issues (toxicity)&#xD;
  </why_stopped>
  <start_date type="Actual">December 11, 2008</start_date>
  <completion_date type="Actual">March 30, 2009</completion_date>
  <primary_completion_date type="Actual">March 30, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of safety as determined by assessing adverse events, vital signs, spirometry, ECGs, telemetry, renal biomarkers, safety labs, and physical examination</measure>
    <time_frame>Part A: 3-4 months; Part B: ~1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma or blood concentrations of study drug</measure>
    <time_frame>Part A: 3-4 months; Part B: ~1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Single Dose, Repeat Dose, Drug-Drug Interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.&#xD;
To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK932121; Rosiglitazone; Rosuvastatin</intervention_name>
    <description>GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.</description>
    <arm_group_label>Single Dose, Repeat Dose, Drug-Drug Interaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 and 50 years of age, inclusive&#xD;
&#xD;
          -  Females of non-childbearing potential (as pre-menopausal females with a documented&#xD;
             tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous&#xD;
             amenorrhea&#xD;
&#xD;
          -  Body weight &gt; 50 kg and BMI within the range 19 - 31 kg/m2 (inclusive)&#xD;
&#xD;
          -  QTcB or QTcF &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive pre-study drug/alcohol screen&#xD;
&#xD;
          -  Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result&#xD;
             within 3 months of screening.&#xD;
&#xD;
          -  A positive test for HIV antibody&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study&#xD;
&#xD;
          -  Participation in a clinical trial with an investigational product within 30 days or 5&#xD;
             half-lives of the investigational product (whichever is longer) prior to start of the&#xD;
             new study&#xD;
&#xD;
          -  Exposure to more than four new drugs or within 12 months prior to the first dosing day&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that would be contraindicated&#xD;
&#xD;
          -  Donation of blood or blood products in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine hCG test at screening or&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  History of sensitivity to heparin or history of heparin-induced thrombocytopenia if&#xD;
             heparin is used to maintain the patency of an intravenous cannula.&#xD;
&#xD;
          -  Asthma or a history of asthma&#xD;
&#xD;
          -  Smoking or history or regular use of tobacco- or nicotine-containing products within 2&#xD;
             months prior to screening&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food Effect</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <keyword>Antimalarial</keyword>
  <keyword>First Time In Human</keyword>
  <keyword>Single Dose</keyword>
  <keyword>Repeat Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111319</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

